Defining and assessing adherence to oral antipsychotics: A review of the literature

Schizophrenia Bulletin

Volumn 32, Issue 4, 2006, Pages 724-742

  Velligan, Dawn I ^a   Lam, Yui Wing Francis ^a   Glahn, David C ^a   Barrett, Jennifer A ^a   Maples, Natalie J ^a   Ereshefsky, Larry ^b   Miller, Alexander L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b CALIFORNIA CLINICAL TRIALS   (United States)

Author keywords

Adherence; Oral antipsychotics; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; CONSENSUS DEVELOPMENT; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG URINE LEVEL; FAMILY COUNSELING; HOSPITALIZATION; HUMAN; MEDLINE; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCINFO; SCHIZOPHRENIA; SELF REPORT; SYSTEMATIC REVIEW; TREATMENT REFUSAL;

ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33748781462     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbj075     Document Type: Article

References (174)

1. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54: 665-667.
2. Weiden P, Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q. 1997;68:377-392.
3. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108.
4. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Ann Pharmacother. 1998;32:749-754.
5. Haynes RB. Introduction. In: Sackett DL, Taylor DW, eds. Compliance in Health Care Baltimore, MD: Johns Hopkins University Press; 1979.
6. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull. 1997;23:637-651.
7. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand. 2000;102(suppl): 83-86.
8. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.
9. Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
10. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13: 177-183.
11. Barker S, Barron N, McFarland B, Bigelow D. A community ability scale for chronically mentally ill consumers: part I. reliability and validity. Community Ment Health J. 1994;30(4):363-383.
12. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-247.
13. Diaz E, Levine HB, Sullivan MC, et al. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry Neurosci. 2001;26:325-329.
14. Abas M, Vanderpyl J, Le Prou T, Kydd R, Emery B, Foliaki SA. Psychiatric hospitalization: reasons for admission and alternatives to admission in South Auckland, New Zealand. Aust N Z J Psychiatry. 2003;37:620-625.
15. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand. 2000;101:119-124.
16. Adams SG Jr, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis. 1993;181: 558-560.
17. Adewuya AO, Ola BA, Mosaku SK, Fatoye FO, Eegunranti AB. Attitude towards antipsychotics among outpatients with schizophrenia in Nigeria. Acta Psychiatr Scand. 2006; 113:207-211.
18. Agarwal MR, Sharma VK, Kishore Kumar KV, Lowe D. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry. 1998;44:92-106.
19. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150:873-9.
20. Arango C, Bombín I, González-Salvador T, García-Cabeza I, Bobes J. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry. 2006; 21:34-40.
21. Ayers T, Liberman RP, Wallace CJ. Subjective response to antipsychotic drugs: failure to replicate predictions of outcome. J Clin Psychopharmacol. 1984;4:89-93.
22. Bachmann S, Bottmer C, Schroder J. Neurological soft signs in first-episode schizophrenia: a follow-up study. Am J Psychiatry. 2005;162:2337-2343.
23. Bechdolf A, Kohn D, Knost B, Pukrop R, Klosterkotter J. A randomized comparison of group cognitive-behavioral therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatr Scand. 2005;112:173-179.
24. Birchwood M, Cochrane R, Macmillan F, Copestake S, Kucharska J, Carriss M. The influence of ethnicity and family structure on relapse in first-episode schizophrenia: a comparison of Asian, Afro-Caribbean, and white patients. Br J Psychiatry. 1992;161:783-790.
25. Boczkowski JA, Zeichner A, DeSanto N. Neuroleptic compliance among chronic schizophrenic outpatients: an intervention outcome report. J Consult Clin Psychol. 1985;53: 666-671.
26. Brown CS, Wright RG, Christensen DB. Association between type of medication instruction and patients' knowledge, side effects, and compliance. Hosp Community Psychiatry. 1987;38:55-60.
27. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res. 2005; 133:129-133.
28. Byerly MJ, Fisher R, Carmody T, Rush AJ. A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66:997-1001.
29. Casper ES, Regan JR. Reasons for admission among six profile subgroups of recidivists of inpatient services. Can J Psychiatry. 1993;38:657-661.
30. Casper ES. Identifying multiple recidivists in a state hospital population. Psychiatr Serv. 1995;46:1074-1075.
31. Chan DW. Medication compliance in a Chinese psychiatric out-patient setting. Br J Med Psychol. 1984;57:81-89.
32. Chen EY, Hui CL, Dunn EL, et al. A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res. 2005;77(1): 99-104.
33. Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand. 2006;113:148-153.
34. Christensen JK. A 5-year follow-up study of male schizophrenics: evaluation of factors influencing success and failure in the community. Acta Psychiatr Scand. 1974;50:60-72.
35. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106:286-290.
36. Cuffel BJ, Alford J, Fischer EP, Owen RR. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis. 1996;184:653-659.
37. Conte G, Ferrari R, Guarneri L, Calzeroni A, Sacchetti E. Reducing the "revolving door" phenomenon. Am J Psychiatry. 1996;153:1512.
38. Dani MM, Thienhaus OJ. Characteristics of patients with schizophrenia in two cities in the U.S. and India. Psychiatr Serv. 1996;47:300-301.
39. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62:717-724.
40. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry. 2004;65:354-360.
41. Dixon L, Weiden P, Torres M, Lehman A. Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry. 1997;154:1302-1304.
42. Dolder CR, Lacro JP, Warren KA, Golshan S, Perkins DO, Jeste DV. Brief evaluation of medication influences and beliefs: development and testing of a brief scale for medication adherence. J Clin Psychopharmacol. 2004;24:404-409.
43. Donohoe G, Owens N, O'Donnell C, et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry. 2001;16:293-298.
44. Dorevitch A, Aronzon R, Zilberman L. Medication maintenance of chronic schizophrenic out-patients by a psychiatric clinical pharmacist: 10-year follow-up study. J Clin Pharm Ther. 1993;18:183-186.
45. Dossenbach M, Arango-Davila C, Ibarra HS, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J Clin Psychiatry. 2005;66:1021-1030.
46. Drake RE, Wallach MA, Teague GB, Freeman DH, Paskus TS, Clark TA. Housing instability and homelessness among rural schizophrenic patients. Am J Psychiatry. 1991;148: 330-336.
47. Drake RE, Wallach MA. Substance abuse among the chronic mentally ill. Hosp Community Psychiatry. 1989;40:1041-1046.
48. Duncan JC, Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci. 1998;43:1133-1137.
49. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther. 2005;27(2):263-272.
50. Eckman TA, Liberman RP, Phipps CC, Blair KE. Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol. 1990;10:33-38.
51. Elbogen EB, Swanson JW, Swartz MS, Van Dorn R. Medication non-adherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. J Nerv Ment Dis. 2005;193:673-679.
52. Falloon IR, Boyd JL, McGill CW, et al. Family management in the prevention of morbidity of schizophrenia: clinical outcome of a two-year longitudinal study. Arch Gen Psychiatry. 1985;42:887-896.
53. Farabee D, Shen H, Sanchez S. Program-level predictors of antipsychotic medication adherence among parolees. Int J Offender Ther Comp Criminol. 2004;48:561-571.
54. Favre S, Huguelet MA, Vogel S, Gonzalez MA. Neuroleptic compliance in a cohort of first episode schizophrenics: a naturalistic study. Eur J Psychiatry. 1997;11:35-42.
55. Fernando ML, Velamoor VR, Cooper AJ, Cernovsky Z. Some factors relating to satisfactory post-discharge community maintenance of chronic psychotic patients. Can J Psychiatry. 1990;35:71-73.
56. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res. 2005;78(2-3):147-156.
57. Frangou S, Sachpazidis I, Stassinakis A, Sakas G. Telemonitoring of medication adherence in patients with schizophrenia. Telemed J E-Health. 2005;11(6):675-683.
58. Frank AF, Gunderson JG. The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Arch Gen Psychiatry. 1990;47:228-236.
59. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65:1372-1376.
60. Gaebel W, Janner M, Frommann N, et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr Res. 2002; 53:145-159.
61. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients: the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry. 1985;18:235-239.
62. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry. 1998;39:215-219.
63. Garcia-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia: a naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1:7.
64. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-699.
65. Giron M, Gomez-Beneyto M. Relationship between family attitudes measured by the semantic differential and relapse in schizophrenia: a 2 year follow-up prospective study. Psychol Med. 1995;25:365-371.
66. Giron M, Gomez-Beneyto M. Relationship between empathic family attitude and relapse in schizophrenia: a 2-year follow-up prospective study. Schizophr Bull. 1998; 24:619-627.
67. Glick ID, Clarkin JF, Haas GL, Spencer JH Jr, Chen CL. A randomized clinical trial of inpatient family intervention: VI. mediating variables and outcome. Fam Process. 1991;30: 85-99.
68. Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int Clin Psychopharmacol. 2002;17:65-68.
69. Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. J Clin Psychiatry. 2003;64:119-122.
70. Gray R, Wykes T, Edmonds M, Leese M, Gournay K. Effect of a medication management training package for nurses on clinical outcomes for patients with schizophrenia: cluster randomised controlled trial. Br J Psychiatry. 2004; 185:157-162.
71. Green JH. Frequent rehospitalization and noncompliance with treatment. Hosp Community Psychiatry. 1988;39: 963-966.
72. Grunebaum MF, Weiden PJ, Olfson M. Medication supervision and adherence of persons with psychotic disorders in residential treatment settings: a pilot study. J Clin Psychiatry. 2001;62:394-399.
73. Grunebaum M, Aquila R, Portera L, Leon AC, Weiden P. Predictors of management problems in supported housing: a pilot study. Community Ment Health J. 1999;35:127-133.
74. Guimâon J. The use of group programs to improve medication compliance in patients with chronic diseases. Patient Educ Couns. 1995;26:189-193.
75. Hamera E, Schneider JK, Deviney S. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. J Nerv Ment Dis. 1995;183:559-565.
76. Hayward P. Medication self-management: a preliminary report on an intervention to improve medication compliance. J Ment Health. 1995;4:511-518.
77. Hertling I, Philipp M, Dvorak A, et al. Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients. Neuropsychobiology. 2003;47:37-46.
78. Hodgins S, Tiihonen J, Ross D. The consequences of conduct disorder for males who develop schizophrenia: associations with criminality, aggressive behavior, substance use, and psychiatric services. Schizophr Res. 2005;78: 323-335.
79. Hoffmann H. Age and other factors relevant to the rehospitalization of schizophrenic outpatients. Acta Psychiatr Scand. 1994;89:205-210.
80. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
81. Holzinger A, Loffler W, Muller P, Priebe S, Angermeyer MC. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia. J Nerv Ment Dis. 2002;190:597-603.
82. Hornung WP, Kieserg A, Feldman R, Buchkremer G. Psychoeducational training for schizophrenic patients: background, procedure, and empirical findings. Patient Educ Couns. 1996;29:257-268.
83. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res. 2002;54:253-264.
84. Ito J, Oshima I. Distribution of EE and its relationship to relapse in Japan. Int J Ment Health. 1995;24:23-37.
85. Jarobe KS, Schartz SK. The relationship between medication noncompliance and cognitive function in patients with schizophrenia. J Am Psychiatr Nurses Assoc. 1999;5:S2-S8.
86. Jerrell JM. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull. 2002;28:589-605.
87. Jeste SD, Patterson TL, Palmer BW, Dolder CR, Goldman S, Jeste DV. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr Res. 2003;63:49-58.
88. Joyce AT, Harrison DJ, Loebel AD, Ollendorf DA. Impact of atypical antipsychotics on outcomes of care in schizophrenia. Am J Manag Care. 2005;11(8suppl):S254-S261.
89. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006;21:29-33.
90. Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O' Callaghan E. Psychopharmacology: insight and comorbid substance misuse and medication compliance among patients with schizophrenia. Psychiatr Serv. 2001;52:161-166.
91. Kamali M, Kelly L, Gervin M, Browne S, Larkin C, O' Callaghan E. The prevalence of comorbid substance misuse and its influence on suicidal ideation among in-patients with schizophrenia. Acta Psychiatr Scand. 2000;101:452-456.
92. Kampman O, Kiviniemi P, Koivisto E, et al. Patient characteristics and diagnostic discrepancy in first-episode psychosis. Compr Psychiatry. 2004;45(3):213-218.
93. Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatr Res. 2002;110:39-48.
94. Kapur S, Ganguli R, Ulrich R, Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr Res. 1992;6:49-53.
95. Kashner TM, Rader LE, Rodell DE, Beck CM, Rodell LR, Muller K. Family characteristics, substance abuse, and hospitalization patterns of patients with schizophrenia. Hosp Community Psychiatry. 1991;42:195-196.
96. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med. 1987;25:1205-1211.
97. Kelly GR, Scott JE. Medication compliance and health education among outpatients with chronic mental disorders. Med Care. 1990;28:1181-1197.
98. Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312:345-349.
99. Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br J Psychiatry. 1998;172:413-419.
100. Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003;6:97-102.
101. Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med. 1998;28:255-263.
102. Klingberg S, Buchkremer G, Holle R, Monking HS, Hornung WP. Differential therapy effects of psychoeducational psychotherapy for schizophrenic patients: results of a 2-year follow-up. Eur Arch Clin Neurosci. 1999;249: 66-72.
103. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509-516.
104. Koukia E, Madianos MG. Is psychosocial rehabilitation of schizophrenic patients preventing family burden? a comparative study. J Psychiatr Ment Health Nurs. 2005; 12(4):415-422.
105. Lecompte D, Pelc I. A cognitive-behavioral program to improve compliance with medication in patients with schizophrenia. Int J Ment Health. 1996;25:51-56.
106. Li Z, Arthur D. Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br J Psychiatry. 2005;187:339-345.
107. Lin IF, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry. 1979; 40:430-432.
108. Linn MW, Klett CJ, Caffey EM Jr. Relapse of psychiatric patients in foster care. Am J Psychiatry. 1982;139: 778-783.
109. Linden M, Godemann F, Gaebel W, et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophr Bull. 2001;27:585-596.
110. Lindstrom LH. A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. Psychopharmacology. 1989;99(suppl):S84-S86.
111. Linszen D, Lenior M, De Haan L, Dingemans P, Gersons B. Early intervention, untreated psychosis, and the course of early schizophrenia. Br J Psychiatry Suppl. 1998; 172(33):84-89.
112. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry. 2003;36:105-112.
113. Macpherson R, Jerrom B, Hughes A. Drug refusal among schizophrenic patients treated in the community. J Ment Health. 1997;6:141-147.
114. Macpherson R, Jerrom B, Hughes A. A controlled study of education about drug treatment in schizophrenia. Br J Psychiatry. 1996;168:709-717.
115. Marom S, Munitz H, Jones PB, Weizman A, Hermesh H. Expressed emotion: relevance to rehospitalization in schizophrenia over 7 years. Schizophr Bull. 2005;31:751-758.
116. Marom S, Munitz H, Jones PB, Weizman A, Hermesh H. Familial expressed emotion: outcome and course of Israeli patients with schizophrenia. Schizophr Bull. 2002;28:731-743.
117. Martic-Biocina S, Baric V. Factors important for compliance among Croatian patients suffering from schizophrenia: how to improve psychiatric services in Croatia? Psychiatr Dan. 2005;17:36-41.
118. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis. 1984;172:412-416.
119. McEvoy JP, Apperson LJ, Appelbaum PS, et al. Insight in schizophrenia: its relationship to acute psychopathology. J Nerv Ment Dis. 1989;177:43-47.
120. McFarlane WR, Lukens E, Link B, et al. Multiple-family groups and psychoeducation in the treatment of schizophrenia. Arch Gen Psychiatry. 1995;52:679-687.
121. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv. 2003;54:719-723.
122. Merinder LB, Viuff AG, Laugesen HD, Clemmensen K, Misfelt S, Espensen B. Patient and relative education in community psychiatry: a randomized controlled trial regarding its effectiveness. Soc Psychiatry Psychiatr Epidemiol. 1999;34:287-294.
123. Nageotte C, Sullivan G, Duan N, Camp PL. Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol. 1997; 32:49-56.
124. Nakonezny PA, Byerly MJ. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophr Res. 2006;82:107-114.
125. Nelson AA Jr, Gold BH, Hutchinson RA, Benezra E. Drug default among schizophrenic patients. Am J Hosp Pharmacy. 1975;32:1237-1242.
126. Ng RMK, Mui J, Chenung HK, Leung SP. Expressed emotion and relapse of schizophrenia in Hong Kong. Hong Kong J Psychiatry. 2001;11:4-11.
127. Norman RM, Malla AK. Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis. J Nerv Ment Dis. 2002;190:331-334.
128. O'Donnell C, Donohoe G, Sharkey L, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003;327:834.
129. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv. 2000;51:216-222.
130. Olfson M, Mechanic D, Boyer CA, Hansell S. Linking inpatients with schizophrenia to outpatient care. Psychiatr Serv. 1998;49:911-917.
131. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
132. Parker G, Hadzi-Pavlovic D. The capacity of a measure of disability (the LSP) to predict hospital readmission in those with schizophrenia. Psychol Med. 1995;25:157-163.
133. Parkin DM, Henney CR, Quirk J, Crooks J. Deviation from prescribed drug treatment after discharge from hospital. BMJ. 1976;2:686-688.
134. Pristach CA, Smith CM. Medication compliance and substance abuse among schizophrenic patients. Hosp Community Psychiatry. 1990;41:1345-1348.
135. Pyne JM, Bean D, Sullivan G. Characteristics of patients with schizophrenia who do not believe they are mentally ill. J Nerv Ment Dis. 2001;189:146-153.
136. Razali MS, Hasanah CI, Che I, Khan UA, Subramaniam M. Psychosocial interventions for schizophrenia. J Ment Health. 2000;9:283-289.
137. Razali MS, Yahya H. Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand. 1995;91:331-335.
138. Rettenbacher MA, Hofer A, Eder U, et al. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry. 2004;65:1211-1218.
139. Rijcken CA, Tobi H, Vergouwen AC, de Jong-van den Berg LT. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerised pharmacy data. Pharmacoepidemiol Drug Safety. 2004;13(6):365-370.
140. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57:209-219.
141. Rosa MA, Marcolin MA, Elkis H. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia. Rev Bras Psiquiatria. 2005; 27(3):178-184.
142. Rosenheck R, Chang S, Choe Y, et al. Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry. 2000;61: 382-386.
143. Ruscher SM, De Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv. 1997;48:82-85.
144. Rzewuska M. Drug maintenance treatment compliance and its correlation with the clinical picture and course of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:811-814.
145. Sellwood W, Tarrier N. Demographic factors associated with extreme non-compliance in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1994;29:172-177.
146. Sellwood W, Barrowclough C, Tarrier N, Quinn J, Mainwaring J, Lewis S. Needs-based cognitive-behavioral family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. Acta Psychiatr Scand. 2001;104: 346-355.
147. Sellwood W, Tarrier N, Quinn J, Barrowclough C. The family and compliance in schizophrenia: the influence of clinical variables, relatives' knowledge, and expressed emotion. Psychol Med. 2003;33:91-96.
148. Seo MA, Min SK. Development of a structural model explaining medication compliance of persons with schizophrenia. Yonsei Med J. 2005;46(3):331-340.
149. Seltzer A, Roncari I, Garfinkel P. Effect of patient education on medication compliance. Can J Psychiatry. 1980;25: 638-645.
150. Serban G, Thomas A. Attitudes and behaviors of acute and chronic schizophrenic patients regarding ambulatory treatment. Am J Psychiatry. 1974;131:991-995.
151. Shvartsburd A, Sajadi C, Morton V, Mirabi M, Gordon J, Smith RC. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients. J Clin Psychopharmacol. 1984;4:194-198.
152. Sibitz I, Katschnig H, Goessler R, Unger A, Amering M. Pharmacophilia and pharmacophobia: determinants of patients' attitudes towards antipsychotic medication. Pharmacopsychiatry. 2005;38(3):107-112.
153. Smith CM, Barzman D, Pristach CA. Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol. 1997;37:147-154.
154. Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry. 1995;152:1749-1756.
155. Suzuki T, Uchida H, Takeuchi H, et al. Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology. 2005;181:566-575.
156. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52:805-811.
157. Svedberg B, Mesterton A, Cullberg J. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc Psychiatry Psychiatr Epidemiol. 2001;36: 332-337.
158. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004;30:3-20.
159. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42:241-247.
160. Trauer T, Sacks T. Mediation compliance: a comparison of the views of severely mentally ill clients in the community, their doctors, and their case managers. J Ment Health. 1998;7:621-629.
161. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62:545-551.
162. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry. 1976;33:1443-1446.
163. Vaughan K, McConaghy N, Wolf C, Myhr C, Black T. Community treatment orders: relationship to clinical care, medication compliance, behavioral disturbance, and readmission. Aust N Z J Psychiatry. 2000;34:801-808.
164. Vauth R, Loschmann C, Rusch N, Corrigan PW. Understanding adherence to neuroleptic treatment in schizophrenia. Psychiatry Res. 2004;126:43-49.
165. Verghese A, John JK, Rajkumar S, Richard J, Sethi BB, Trivedi JK. Factors associated with the course and outcome of schizophrenia in India: results of a two-year multicentre follow-up study. Br J Psychiatry. 1989;154:499-503.
166. Weiden P, Rapkin B, Zygmunt A, Mott T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv. 1995;46:1049-1054.
167. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
168. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medic-aid patients with schizophrenia. Psychiatr Serv. 2004;55: 886-891.
169. Weiss KA, Smith TE, Hull JW, Piper AC, Huppert JD. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull. 2002;28:341-349.
170. Xiong W, Phillips MR, Hu X, et al. Family-based intervention for schizophrenic patients in China: a randomised controlled trial. Br J Psychiatry. 1994;165:239-247.
171. Yamada K, Watanabe K, Nemoto N, et al. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study. Psychiatry Res. 2006;141:61-69.
172. Yen CF, Chen CS, Ko CH, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci. 2005;59(4):403-409.
173. Ziguras SJ, Klimidis S, Lambert TJ, Jackson AC. Determinants of anti-psychotic medication compliance in a multicultural population. Community Ment Health J. 2001;37: 273-283.
174. Bendle S, Velligan DI, Mueller JL, Davis BV, Ritch JL, Miller AL. The Med-eMonitor™ for improving adherence to oral medication in schizophrenia. Schizophr Bull. 2005;31:519.